Meta-analysis of the efficacy and safety of Xingnaojing combined with edaravone in the treatment of acute ischaemic stroke
Objective To systematically evaluate the efficacy and safety of Xingnaojing combined with edaravone as a therapy for acute ischemic stroke.Methods PubMed,CNKI,VIP,Wanfang and SinoMed databases were systematically searched,and the literature was screened according to the inclusion/exclusion criteria.Two authors independently extracted and checked the data of the included literature.The outcome data were combined and analyzed using RevMan software.Results Twenty-four randomized controlled trials were included.The outcome suggested that combining Xingnaojing and edaravone on the basis of conventional therapy was superior to conventional therapy that did not use both simultaneously in improving the rate of neurological improvement[RR=1.25,95%CI(1.20,1.31),P＜0.000 01]),improving viability[MD=12.40,95%CI(1.56,23.23),P=0.02],lowering NIHSS scores[MD=-3.79,95%CI(-5.34,-2.24),P＜0.000 01],and reducing coma degree[MD=1.77,95%CI(0.77,2.77),P=0.000 5];there was no statistical difference in the incidence of all-cause mortality[RR=0.60,95%CI(0.08,4.46),P=0.62]and adverse events between groups[RR=0.75,95%CI(0.36,1.56),P=0.44].Conclusion The combination of Xingnaojing and edaravone in patients with acute ischemic stroke can enhance efficacy in improving neurological function,improving viability,improving neurological recovery level(reducing NIHSS score),and reducing coma degree without increasing safety risks.
万方数据
维普
